Home About Us Press Releases

Press Releases

2020-04-30

FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies

HILLERØD, Denmark, April 30, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), today announced that it will reserve manufacturing…

Read more

2020-04-23

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

BILLINGHAM, United Kingdom, April 23, 2020 /PRNewswire/ — FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry…

Read more

2020-03-18

Fujifilm Invests $83M USD to Expand FUJIFILM Diosynth Biotechnologies Microbial Capacity

TOKYO, March 18, 2020 — FUJIFILM Corporation announced today that it will invest approximately 9 billion yen ($83M USD) to expand the microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB).

Read more

2020-03-16

Christine Vannais is appointed as FDB’s North Carolina Site Chief Operating Officer

Christine joined FDB in 2012 and she has led the North Carolina Manufacturing Operations team since 2014 as part of the Site Leadership Team.

Read more

2020-03-12

FDB commences construction of planned UK BioCampus expansion

FDB commences construction of planned UK BioCampus expansion.

Read more

2020-02-28

FUJIFILM Diosynth Biotechnologies expands its Gene Therapy Manufacturing Capacity

Capacity increase will support production of high throughput and large volume gene therapy products.

Read more

2020-02-25

FUJIFILM Diosynth Biotechnologies expands North Carolina Facility

FUJIFILM Diosynth Biotechnologies expands North Carolina Facility

Read more

2019-12-03

FUJIFILM Diosynth Biotechnologies Named A Top Ten Healthiest Employer Nationally

FUJIFILM Diosynth Biotechnologies Named A Top Ten Healthiest Employer Nationally

Read more

2019-11-25

FUJIFILM Diosynth Biotechnologies is Founding Member of the New Center of Innovation and Manufacturing in Boston, MA

FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics and gene therapy Contract Development and Manufacturing Organization (CDMO) has announced its participation as a founding member in a newly announced center for innovation and manufacturing of next-generation medicines.

Read more

2019-11-14

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES $55 MILLION USD INVESTMENT TO EXPAND GENE THERAPY DEVELOPMENT CAPABILITIES

FUJIFILM Diosynth Biotechnologies will be expanding its gene therapy process and analytical development capabilities with the addition of new dedicated laboratories

Read more

2019-11-04

Top Honors in TBJ’s 2019 HEALTHIEST EMPLOYER

FUJIFILM DIOSYNTH BIOTECHNOLOGIES NAMED A 2019 HEALTHIEST EMPLOYER

Read more

2019-08-01

FUJIFILM Completes Acquisition of Biogen’s Manufacturing Site in Denmark

Fujifilm Completes Acquisition of Biogen’s Manufacturing Site in Denmark Tokyo, August 1, 2019 ‒ FUJIFILM Corporation (“Fujifilm”) today announced that it has completed the acquisition…

Read more

2019-06-06

FUJIFILM introduces a Novel, Fully Integrated Continuous Production System

TOKYO, June 5, 2019 /PRNewswire/ — FUJIFILM Corporation (President: Kenji Sukeno), today announced an initial $10M USD investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture…

Read more

2019-04-30

FUJIFILM Announces Expansion Of Its Cell Culture Process Development Labs

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES EXPANSION OF ITS CELL CULTURE PROCESS DEVELOPMENT LABS AND THE CREATION OF A NEW BIOCAMPUS AS PART OF EXPANSION TO ITS…

Read more

2019-04-11

Fujifilm Introduces A 10 Week Cell Line Development Timeline, Apollo™ X

FUJIFILM ANNOUNCES THE INTRODUCTION OF A 10 WEEK CELL LINE DEVELOPMENT TIMELINE WITH ITS APOLLO™ X ADVANCED MAMMALIAN EXPRESSION SYSTEM The timeline maintains a robust cloning strategy with one round of cloning. Billingham, U.K., April 11,…

Read more

2019-03-12

Fujifilm To Acquire Large-Scale Biologics Manufacturing Site From Biogen

FUJIFILM Corporation today announced that it has entered into an agreement to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen for approximately US$890 million in cash.

Read more

2019-01-31

FUJIFILM ANNOUNCES THE CREATION OF A STRATEGIC PARTNERSHIP PROGRAM TO FURTHER DEVELOP ITS CAPABILITIES IN BIOPROCESSING

Billingham, UK, January 31, 2019 ‒ FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture…

Read more

2019-01-15

FUJIFILM announces the extension of its Fill Finish services to include recombinant protein aseptic filling market.

FUJIFILM Corporation (President: Kenji Sukeno, Fujifilm), has announced the extension of its Fill/Finish services to include cGMP aseptic filling of recombinant proteins. These services will…

Read more

2019-01-10

FUJIFILM Launches Next Generation APOLLO™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies,…

Read more

2019-01-07

FUJIFILM to Invest 10 Billion Yen in its BIO CDMO Business

FUJIFILM Corporation (President: Kenji Sukeno) announced plans to invest approximately JPY 10 billion (approximately $90 million U.S. dollars) in order to expand its Bio Contract…

Read more

2018-12-07

Announcement of Co-Chair Role for CEO, Steve Bagshaw

FUJIFILM Diosynth Biotechnologies Announces Co-Chair Role Of Its CEO, Steve Bagshaw, In The Preparation Of The United Kingdom’s Bioeconomy Growth Strategy

Read more

2018-11-01

FUJIFILM Announces AMECRYS Collaboration Reaches Project Milestone

FUJIFILM announces that AMECRYS Collaboration reaches project milestone to develop new technologies to improve Downstream Processing of Monoclonal Antibodies

Read more

2018-07-27

Fill Finish Service Expansion to Gene Therapy & Viral Vaccine

Announcement of the extension of its gene therapy and viral vaccine Fill/Finish capabilities to provide services in support of late phase candidates and commercial supply….

Read more

2018-05-31

Opening of Cambridge Collaboration Center in Cambridge, MA

At BIO 2018 FUJIFILM announces the opening of Cambridge Collaboration Center to expand its footprint

Read more

2018-01-24

New Flexible Manufacturing Facility Opens

FUJIFILM ANNOUNCES THE OPENING OF ITS FLEXIBLE MANUFACTURING FACILITY FOR THE PRODUCTION OF CLINICAL AND COMMERCIAL GENE THERAPIES FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract…

Read more

2018-01-18

cGMP Readiness of Saturn™ mAb Facilities

FUJIFILM Corporation (President: Kenji Sukeno) today announced the on-time completion of Qualification activities, enabling commencement of cGMP operations for its Saturn™ mAb manufacturing facilities at FUJIFILM Diosynth Biotechnologies (“FDB”), a world leading cGMP Contract Development and Manufacturing Organization in College…

Read more

2018-01-03

Biotech Showcase 2018 Presentation

FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the…

Read more

2017-11-21

Bagshaw Awarded N.E. Business Executive of the Year

FUJIFILM Diosynth Biotechnologies, a leading global Contract Development and Manufacturing Organization (CDMO), is pleased to announce that its Chief Executive Officer, Steve Bagshaw, has been awarded “North East Business Executive of the Year 2017”; a prestigious award organized by The…

Read more

2017-11-06

CDMO Business Expansion

FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2billion yen on its CDMO* sites in the U.S.A. and the U.K. in order to accelerate the expansion of the company’s business for developing and manufacturing biopharmaceuticals** under contract…

Read more

2017-09-12

FUJIFILM Diosynth Biotechnologies Opens Cell Culture Process Development Laboratories

FUJIFILM Diosynth Biotechnologies has announced its opening of the 10,000 square foot, state-of-the-art cell culture Process Development Laboratories in Wilton Centre, Teesside. These laboratories were realized through a JPY1 billion ($9M USD) investment which is part of the greater JPY14…

Read more

2017-06-20

Completion of 100th pAVEway Program

FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention…

Read more

2017-04-18

New Process Development Facility Investment

FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the…

Read more

2017-03-01

Saturn mAb Platform™ to Support cGMP Manufacturing

FUJIFILM Diosynth Biotechnologies, has announced the expansion of its Monoclonal Antibody development and manufacturing services with the introduction of its Saturn mAb Platform™. Read the…

Read more

2017-02-28

New Bio CDMO Division

FUJIFILM Launches Bio CDMO Division to Expand cGMP Contract Development and Manufacturing Operations Aiming to achieve 100 billion yen in revenue by FY2024/March READ MORE

Read more

2016-06-06

New Microbial Biologics Facility

Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility for use by its Contract Development and Manufacturing Customers Billingham, U.K.,  June 6, 2016…

Read more

2016-05-09

New Laboratory Facility – Research Triangle Park, NC

FUJIFILM Diosynth Biotechnologies Opens New Laboratory Facility in Research Triangle Park, NC MORRISVILLE, N.C., May 9, 2016 – FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Biologics…

Read more

2016-05-05

Phase I Clinical Trial of Anti-Cancer Agent

Department taps Centers for Innovation in Advanced Development and Manufacturing

Read more

2015-01-13

Laboratory Facility in Research Triangle Park, NC

Fujifilm Diosynth Biotechnologies breaks ground on laboratory facility in Research Triangle Park, NC MORRISVILLE, N.C., January 13, 2015 – FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a…

Read more

2014-12-31

New Years’ Honours List

MBE for Fujifilm Diosynth Biotechnologies’ Subhash Chaudhary in new years’ honours list Billingham : 31st December 2014 : FUJIFILM Diosynth Biotechnologies is delighted to announce…

Read more

2014-12-18

Fujifilm completes acquisition of Kalon Biotherapeutics

Fujifilm completes acquisition of Kalon Biotherapeutics Morrisville, North Carolina and College Station, Texas – December 18, 2014. FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (FDBU), a FUJIFILM…

Read more

2014-10-09

‘Apollo™’ mammalian expression platform

Fujifilm Diosynth Biotechnologies announces the launch of its ‘Apollo™’ mammalian expression platform Billingham, Teesside, UK and Research Triangle Park, NC, USA, 9th October 2014 :…

Read more

2014-09-16

Fujifilm chooses ambr250 mini bioreactor system

Fujifilm chooses ambr250 mini bioreactor system to optimise its fermentation process development TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier…

Read more

2014-08-24

Significant Improvement of SYN-004

Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile Rockville, MD, August 28,…

Read more

2014-08-19

Two New 2,000L Single-use Bioreactors

FUJIFILM Diosynth Biotechnologies expands cell culture manufacturing capacity with addition of two new 2,000L single-use bioreactors Billingham, Teesside, UK and Research Triangle Park, NC, USA,…

Read more

2014-06-23

Expansion of R&D Facilities

FUJIFILM Disoynth Biotechnologies continues Expansion of R&D Facilities including addition of Latest High Throughput Equipment Fujifilm Diosynth Biotechnologies has announced continued expansion of its process development…

Read more

2013-10-09

FUJIFILM receives MHRA

FUJIFILM Diosynth Biotechnologies’ UK site receives MHRA Manufacturing License FUJIFILM Diosynth Biotechnologies has announced that it has received a renewal of its Manufacturer’s Licence from…

Read more

2013-10-02

New Manufacturing Facility

FUJIFILM Diosynth Biotechnologies’ Opens New Manufacturing Facility FUJIFILM Diosynth Biotechnologies today formally opened its new mammalian cell culture cGMP manufacturing facility at a ceremony performed…

Read more

2013-07-18

Evaluating Synthetic Biologics’ SYN-004

FUJIFILM Diosynth Biotechnologies to Evaluate of Synthetic Biologics’ Propietary Beta-Lactamase Enzyme, SYN-004 Rockville, MD, July 18, 2013 – Synthetic Biologics, Inc. (NYSE MKT: SYN), a…

Read more

2013-04-22

New Cell Banking Facility at Billingham, UK Site

FUJFILM Diosynth Biotechnologies commissions new cell banking facility at Billingham, UK Site FUJIFILM Diosynth Biotechnologies has announced that it has commissioned on time its new…

Read more

2012-10-24

FUJIFILM Diosynth Biotechnologies Announces Strategic Alliance

FUJIFILM Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates FUJIFILM Diosynth Biotechnologies has announced it has entered into a…

Read more

2012-03-23

FUJIFILM expands R&D Capabilities

FUJIFILM Diosynth Biotechnologies expands R&D Capabilities at its Billingham, UK Site FUJIFILM Diosynth Biotechnologies has completed the first phase of a 3m ($4.5m) investment in…

Read more

2011-10-25

Collaboration for Novel Anti-Staph Biologic

FUJIFILM Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Novel Anti-Staph Biologic FUJIFILM Diosynth Biotechnologies and ContraFect Corporation announced today that they…

Read more

2011-06-01

FUJIFILM Expands Mammalian Cell Culture Capacity

FUJIFILM Diosynth Biotechnologies Expands Mammalian Cell Culture Capacity FUJIFILM Diosynth Biotechnologies is expanding its existing contract manufacturing capabilities with the addition of a 1,000L Xcellerex…

Read more

2011-04-01

FUJIFILM Completes Acquisition of Merck

FUJIFILM Completes Acquisition of Merck Biomanufacturing Network FUJIFILM Diosynth Biotechnologies has been announced as the new name for the former Merck BioManufacturing Network (known as…

Read more

2011-02-28

FUJIFILM to Acquire Merck

FUJIFILM to Acquire Merck Biomanufacturing Network TOKYO and WHITEHOUSE STATION, NJ., February 28, 2011 – FUJIFILM Corporation and Merck (NYSE:MRK), known as MSD outside the United…

Read more

2010-09-30

MSD Signs Deal with ThromboGenics

MSD Signs Deal with ThromboGenics for Long-term Commercial Supply of Microplasmin Leuven, Belgium – 30 September, 2010 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company…

Read more